Last reviewed · How we verify

Anergis — Portfolio Competitive Intelligence Brief

Anergis pipeline: 1 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 2 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AllerT AllerT marketed Allergen immunotherapy (peptide-based) Allergen-derived peptide epitopes Immunology / Allergy

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ALK-Abelló A/S · 1 shared drug class
  2. Allergopharma GmbH & Co. KG · 1 shared drug class
  3. Beijing Tongren Hospital · 1 shared drug class
  4. HAL Allergy · 1 shared drug class
  5. Johns Hopkins University · 1 shared drug class
  6. Laboratorios Leti, S.L. · 1 shared drug class
  7. Medical University of Silesia · 1 shared drug class
  8. National Taiwan University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Anergis:

Cite this brief

Drug Landscape (2026). Anergis — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anergis. Accessed 2026-05-13.

Related